there, neutrophils further trigger the release of proinflammatory mediators and chemoattractants, thus perpetuating the inflammatory response (3) .
Simple and non-invasive biomarkers are urgently needed to monitor disease progression, identify pulmonary exacerbations and inflammation, and evaluate the efficacy of novel therapies (4) . Such biomarkers would be particularly useful for young children with CF, in whom lower airway secretions are difficult to obtain. The design of clinical trials in CF is hampered, in part, by the lack of sensitive measures of treatment response. The most established outcome measure for CF therapies is FEVI' a functional measure of airflow limitation, and a key consideration in the advancement of treatments from phase 2 to phase 3 trials. Limitations of FEV! endpoint.include the fact that it is relatively insensitive to early disease and has avery limited ability to detect regional heterogeneity of disease. Many of the measurements of surrogate endpoints, including FEVl' cannot be made in uncooperative young children, and they assess function rather than structure (5) .
Assessment of cytokines in sputum and exhaled breath condensate (EBC) may be a promising tool in patients with CF. Cytokine levels in sputum have been shown to be regulated by antibiotic therapy (6) (7) (8) , but few data are available on the duration of the effect of antibiotic treatment and whether cytokines can be more sensitive biomarkers than spirometric parameters. Several research groups detected altered biomarkers of inflammation in EBC of CF patients, compared with controls (9) (10) (11) . However, simultaneous data on multiple markers in CF EBC are limited.
In clinical studies, a multi-analyte profiling approach provides more information on the cytokine network than a single-analyte measurement, as several cytokines are tested in real time per sample. In this pilot study, we studied the simultaneous presence of twelve biomarkers by a biochip array in sputum and EBC in CF patients before and after intravenous (i.v.) antibiotics given for an acute exacerbation. Differently from our previous study (6) where cytokine levels were studied at one defined time point after therapy, to evaluate their changes as compared with respiratory functions tests and systemic markers, we considered the levels of these biomarkers at different time points, i.e. before, during therapy and 15 days after the end of the treatment.
MATERIALS AND METHODS

CF patients
We considered 24 CF patients who were admitted to the CF Centre of the University of Milan for i.v. antibiotic therapy during an acute respiratory exacerbation. Demographics, CFTR genotype and sputum microbiological findings are summarised in Table I . Exacerbation was defined as a deterioration in symptoms perceived by the patient and included an increase in cough, sputum production, dyspnea, decline in forced expiratory volume in 1 sec (FEV1) compared with previous best, weight loss and fever (12) . Inclusion criteria were age> 6 years and FEV! > 40%. Exclusion criteria were infection with multi-resistant S. aureus and B. cepacia complex. Two antibiotics were used in most patients with different mechanisms of action, the choice of which was determined by the sensitivity of the cultured bacteria; all antibiotics were administered at the doses recommended in CF (13) . The 16 patients predominantly infected by P aeruginosa were treated with ceftazidime or meropenem plus tobramycin intravenously for 15 days and the others with beta-lactams plus levofloxacin and/or aztreonam. Other drugs taken by the patients during the study included~2-agonists, mucolytic agents (DNase and hypertonic saline), multivitamin preparations, and pancreatic enzymes.
The study was designed to evaluate patients before and after 6 and 15 days of i.v. antibiotic treatment, as well as after 15 days from the treatment interruption. The protocol was approved by the Institutional Review Board of the University of Milan. Informed consent was obtained from all patients or their parents. All patients underwent routine laboratory determinations, including white blood cell (WBC) counts (n/mm'), C Reactive Protein (CRP; mg/dl), chest x-ray, and sputum cultures. FEV! and forced vital capacity (FVC) were assessed by standard spirometry (Medgraphics PFIDH, Medical Graphics Corporation, St. Paul, MN) and expressed as the percentage of predicted values, based on age, gender, and height (14) .
Collection ofsputum and EBC samples
Sputum samples were collected by spontaneous coughing, and were immediately vortexed and then centrifuged for 5 min at 7,000 x g. Each supernatant was immediately removed and stored in aliquots at -20 D C for up to 2 months prior to testing and then was used undiluted. Samples out of calibration curve were diluted 1:10 in the diluent (buffer) provided before rerunning. We have already validated this procedure through quantification of sputum cytokines by an immunometric assay, demonstrating that it is reproducible and is not hampered by proteolytic degradation (15) .
EBC collection was in agreement ofAmerican Thoracic Society (ATS)/European Respiratory Society (ERS) recommendations (16) . EBC samples were collected by a condensing device formed by two glass chambers (Incofar Sri, Modena, Italy). The inner glass chamber was cooled by means of ice and suspended in a larger glass chamber. The patients were instructed to tidally breathe by the mouth through a two-way non-rebreathing valve for 20 min. To minimize salivary contamination the twoway valve served as a saliva trap, with a 12 em banded tube vertically positioned between the mouthpiece and the condenser (EcoScreen, Jaeger Toennies, Hoechberg, Germany) while the mouth of the subject remained at a lower position in respect to the inlet of the device. In addition, the patients were asked to swallow their saliva periodically. This yielded approximately 1 ml ofEBC. All samples were stored at -80°C up to 6-8 months prior to testing and then used undiluted.
Biomarker measurement
Sputum analytes [IL-la, IL-II3, IL-2, IL-4, IL-6, IL-8, IL-1O, IFN-y, EGF (epidermal growth factor), MCP-l (monocyte chemotactic protein 1), VEGF (vascular endothelial growth factor), TNF-a] were quantified simultaneously by means of the Evidence" biochip array technology (Randox Laboratories Ltd, Crumlin, County Antrim, UK) on a semi-automated instrument (Evidence Investigator system) (17) . For EBC analytes, an array about 10 times more sensitive than that for sputum (Cytokine and growth factors high-sensitive array, Randox) was used (18) . The biochip used consists of a 9 x 9 mm substrate on which discrete test regions had been constructed. The binding ligands (antibodies) were 'attached to predefined sites on the chemically modified surface of the biochip. After a simple ELISA procedure, each spot was imaged to capture chemiluminescent signal generated at each spot on the array. The light signal was captured by a supercooled charge coupled device (CCD) camera as part of an imaging station and converted by image-processing software to provide results compared with calibration curves for each location on the biochip (17) .
The sensitivity of the sensitive biochip array in 57 control samples ranged from 1.2 pg/ml for IL-6 to 14.6 pg/ml for VEGF (17, 19) . In sputum, seven cytokines were quantitatively measurable in all the samples studied; considering the time points studied altogether, IL-6 was quantitatively reported in 86% of samples, IL-2 in 73% of samples, IL-4 in 67% of samples, IL-I0 in 50% of samples, and IFN-y in 33% of samples.
The sensitivity of the high-sensitivity array immunoassay in 34 normal serum samples spanned from 0.12 pg/ml for IL-6 to 2.12 pg/ml for IL-4 (18) . In EBC, IL-4, IL-l a and IL-113 were quantitatively measurable in all the samples studied. For all the other cytokines, and considering the time points altogether, the detectability ranged from 87% ofsamples for VEGF to 18% ofsamples for IL-1O.
Statistical analysis
As the variables did not show a Gaussian distribution (Kolmogorov-Smimov test), a non-parametric analysis was performed. The Mann-Whitney test was used to determine whether changes in each variable were statistically significant. Data are presented as mean ± standard error ofthe mean, unless differently specified. The Spearman rank correlation test was used for correlation of pulmonary function tests and biomarkers in sputum and EBC samples, and the Spearman correlation coefficient is reported (rJ Multivariate linear regression analysis was performed considering clinical parameters (FEV!, FVC or CRP) as dependent variables and levels in sputum and exhaled breath condensate as independent variables. Statistical tests were two-sided, and significance was determined at the 0.05 level. Analyses were performed using STATAMP 10.0 and EpiInfo 3.3.
RESULTS
Cytokines and growth factor levels in sputum
A change in all the cytokines and growth factors considered occurred over the study period, although with different patterns (Table II) . IL-l a, IL-l~, IL-4, IL-6, IL-lO, TNF-a, IL-8, and VEGF levels decreased already at day 6 of therapy and remained constantly lower than baseline, while MCP-l and EGF levels increased. Of the cytokines which decreased upon antibiotic treatment, only IL-6 was at higher levels than baseline at 1 month posttreatment, confirming our previous data in which we did not find a significant change in IL-6 levels following antibiotic therapy (6) . IFN-y and IL-2 showed a bimodal behaviour: they increased at 6 days and then decreased to values below the baseline at the other time points. Fig. 1 illustrates differences that were significant for IL-l~, IL-4 and VEGF (decreased at all time points considered), IL-l a and IL-IO (decreased at 15 days), TNF-a (decreased at 6 *** 30 days) , and EGF (increased at 15 days).
The steepest change was observed with IL-II3, which, at day 6, was 22.38 % of the baseline level, followed by IL-Ia (55.82%) and TNF-a (56.70 %). The most dramatic change at day 30 was observed with IL-l 0, presenting 26.33 % of the baseline levels (Table II) .
Cytokines and growth factor levels in exhaled breath condensate
Since our preliminary attempts to measure cytokines in EBC generally failed in the first 10 patients enrolled, likely for dilution issues, we used an ultra-sensitive array biochip. Cytokine levels were studied in EBC of further 14 CF patients before and after antibiotic treatment. In their behaviour, cytokines levels appeared to change differently (Table III) . However, it is worth notice that IL-l p, IL-I0, VEGF, and IFN-y levels were always lower at all the time points post-treatment than baseline. Nevertheless, no significant differences were found for all cytokines and growth factors at all the time points considered. At day 6, the 'steepest change was observed with VEGF (49.90%) and IL-IP (49.69%) when compared with the baseline levels (Table III) . The most dramatic decrease was observed with IFN-y, at day 30, with 18% of the baseline level.
Pulmonaryfunction tests and CRP
There was a significant improvement in FVC and FEV! in association with i.v. antibiotics (Table  IV) . This improvement was long-lived, as FVC and FEV! remained significantly higher than baseline for all the duration of the study. CRP demonstrated a significant reduction for a limited time, i.e. for 15 days from the beginning of the antibiotic treatment (Table IV) .
Correlation between sputum levels and clinical variables
Before therapy, VEGF negatively correlated with FEV 1 and FVC, and IL-IP with FEV l • IL-4 negatively correlated with FEV! and FVC at 30 days. IL-8 negatively correlated with FEV! at 15 days, and IL-IP with FEV! andFVC at 15 days. EGF positively correlated with FEV! and FVC at 6 days.
Before therapy, VEGF and IL-l p levels positively correlated with CRP. IL-4, IL-6, IL-8, IL-lO, TNFa and IL-l p positively correlated with CRP after therapy ( Table V) .
The multivariate regression analysis revealed a significant correlation before therapy between FVC and IL-I0 (r s= -0.0002651; p= 0.019). Before therapy, CRP correlated with IL-6 (r s = 0.029064; p= 0.002), IL-I0 (r s= 0.029064; p= 0.002), VEGF (r s=0.0055093; p= 0.000), IL-IP (r s= 0.0042848; p= 0.009) and EGF (r s= 0.0044274; p= 0.019). After 15 days therapy CRP correlated with IL-IO (r s= 0.0446581; p= 0.019), IFN-y (r s= 0.0453217; p= 0.030), TNF-a (r s= 0.0059708; p= 0.011), and IL-la (r s= -0.0016339; p= 0.022).
Correlation between exhaled breath condensate levels and clinical variables
Before therapy, MCP-l negatively correlated with FEV! and FVC, and IFN-y and TNF-a with FVC. After therapy, VEGF negatively correlated with FEV! and FVC at 30 days. IL~8 negatively correlated with FVC at 15 days. Of note, IL-8 levels positively correlated with CRP (Table V) .
The multivariateregressionanalysis did not reveal a significant correlation between clinical variables and cytokine/growthfactor levels at any time point. 
DISCUSSSION
In this study,we found that VEGF and IL-l~levels in sputum significantly correlated with respiratory function and CRP before starting antibiotic therapy for an acute exacerbation in CF patients. However, the multivariate analysis found a strong association between VEGF and IL-l~levels with CRP only. CRP has been found to be a marker of lung disease severity (20) , thus our results strongly suggest that VEGF and IL-l~may be useful as outcome measures to assess acute exacerbations in CF. IL-l is a cytokine produced by macrophages together with TNF-a, and plays a pivotal role in the first phases of acute inflammation and immune response (21) . IL-l and TNF-a can in turn drive epithelial cell production of pro-inflammatory molecules, such as IL-6 and IL-8, to recruit neutrophils (22) . VEGF lot. J. ImmooopathoI. Pharmacol. is chemoattractant for monocytes and therefore is involved in physiologic and pathologic tissue growth and vascular remodelling as well as inflammation (23) (24) . Serum levels of VEGF are increased in CF and correlate with disease severity measured as FEV1 (25) . The bronchial circulation is increased in CF (26) , and VEGF-mediated angiogenesis may be an important pathologic mechanism in the progression of CF lung disease. After 15 days from the beginning of therapy, IL-8 negatively correlated with the FEV" confirming our previous results (6) . Thus, IL-8, the major chemokine for neutrophils, shows to be sensitive to i.v. antibiotics. On the other hand, after 15 days from the end of the therapy, IL-4 was the only cytokine to negatively correlate with the respiratory function. IL-4 is a T(H)2 cytokine which is up-regulated in peripheral blood mononuclear cells obtained from CF patients (27) and is elevated in bronchoalveolar lavage fluid of P. aeruginosa-infected CF patients compared with non-infected patients and healthy controls (28) . Overall, our data indicate that i.v. antibiotics down-regulate the innate immune response in CF airways followed by the dampening of the T(H)2 response.
IL-4, IL-6, IL-8, IL-IO and TNF-o, positively correlated with CRP during therapy, and IL-4 positively correlated with CRP at I month from the start oftherapy. Since IL-IO and TNF-o,? were found to also have a strong association with CRP, they may represent a marker ofreduction in some events in lung inflammation, which are reflected by CRP reduction. Furthermore, IL-IO showed the most dramatic change at day 30, presenting 26.33% of the baseline levels. IL-IO is a pleiotropic cytokine, presenting anti-inflammatory and immunosuppressive activities and also has a role in controlling chronic infections (29) . Thereby, it is possible that in the context of CF lung, its decrease may have a positive effect on the immune response to pathogens. Interestingly, sputum IL-8, TNF-o, and IL-IO levels were significantly decreased following inhaled corticosteroids in preterm infants with chronic lung disease (30) .
EBC has been acknowledged to be of limited value, due to the low levels of inflammatory biomarkers in CF (10) (11) . We then used an ultrasensitive biochip array, with the result that some biomarkers were at the limit of detection. The univariate analysis demonstrated that MCP, IFN-y and TNF-a levels in EBC negatively correlated with spirometric variables and that IL-8 levels positively correlated with CRP before therapy. VEGF was the only growth factor to negatively correlate with FEV1 and FVC 15 days after the end of i.v. antibiotics. Further studies are needed to study the presence and levels of these cytokines in EBC as biomarkers of an acute exacerbation and response to therapy in CF.
In conclusion, a number of sputum biomarkers showed a significant decrease during therapy, suggesting that a panel of different cytokines and growth factors may be more useful biomarkers of response to therapy than one single systemic marker. However, because of the small number of patients included in this study, these initial observations need to be verified in larger groups of patients. Another limitation of our study is that we could not consider routinely collected sputum and EBC biomarkers during times of clinical stability, making it not possible at the moment to evaluate the predictiveness of sputum and EBC biomarkers on the clinical state. The multi-analyte profiling approach used in this study, revealing a panel of correlation estimates between lung function parameters, a systemic inflammatory marker and sputum cytokines/growth factors, may aid in developing future CF-related antiinflammatory intervention strategies.
